L&C Bio Unveils Injectable 'Ozempic Face' Solution From Donated Fat, Eyes Late 2027 Launch
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
South Korean biotech firm L&C Bio is making waves with a new injectable treatment designed to tackle 'Ozempic face,' the unwanted facial volume loss caused by popular GLP-1 weight-loss drugs. The product, tentatively named MegaAdipoECM, uses donated human fat to naturally restore hollow cheeks and sagging skin, offering a much-anticipated solution for millions undergoing rapid weight loss. This innovative approach comes as demand for aesthetic fixes for GLP-1 side effects skyrockets, with J.P. Morgan Research predicting the U.S. GLP-1 patient base to swell from 12.9 million in 2026 to over 30 million by 2030, fueling a significant market. L&C Bio, already a pioneer in K-beauty with its Re2O treatment using donated skin, overcame a major hurdle this year when South Korean law changed to reclassify donated fat from medical waste, clearing the path for domestic production and a more cost-effective supply chain. While the technology is patented in South Korea, the U.S., and China, L&C Bio expects to launch MegaAdipoECM in late 2027, following a one-year grace period imposed by the recent regulatory changes. Beyond 'Ozempic face,' the product is also being positioned as a biological alternative to silicone breast implants, potentially expanding its market reach significantly and driving debate over the ethical use of donated human tissue for cosmetic procedures.